LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that it is investigating potential claims on behalf of investors of Sientra, Inc. ("Sientra" or the "Company") (NASDAQ:SIEN) concerning the Company’s and its officers’ possible violations of federal securities laws in connection with Sientra’s alleged intentional misleading of investors regarding its compliance with relevant safety and production standards.
On September 23, 2015, the Company announced the closing of a public offering of 3 million shares of common stock. Then on September 24, 2015, the Company disclosed that the U.K.’s Medicines and Healthcare products Regulatory Agency has suspended distribution of its Silimed products. On this news the Company’s shares fell $10.88 per share, or over 52%, to close on September 24, 2015 at $9.70 per share. Investors have been damaged by this alleged disclosure of fraud, and GPM is preparing a lawsuit to recover damages on behalf of Sientra investors.
If you purchased Sientra securities, have information or would like to learn more about these claims including whether you qualify to serve as a class representative, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
